CytoSorbents – $11.5 Million Shelf Takedown

New York – April 19, 2017 – Cooley advised the underwriters on CytoSorbents’ $11.5 million shelf takedown of 2,555,555 shares of common stock.

Cowen and Company acted as the sole book-running manager for the offering. Aegis Capital Corp, Wainwright & Co., B. Riley & Co., Maxim Group LLC and Northland Capital Markets acted as co-managers.

CytoSorbents, which trades on The NASDAQ Capital Market under the symbol “CTSO,” is a leader in critical care immunotherapy. The company’s blood purification technology is approved in the European Union, with distribution in 29 countries around the world. CytoSorb is an extracorporeal cytokine adsorber, designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Div Gupta Partner, New York
Daniel I. Goldberg Partner, New York
Josh Kaufman Partner, New York
Pia Kaur Associate, San Francisco
Esther Cho Associate, Boston
Sarah diFrancesca Partner, New York
Bill Christiansen Partner, Seattle
Aaron Nudelman Associate, Seattle
Mark Windfeld-Hansen Partner, Palo Alto
Stephanie Gentile Partner, New York
Francis Wheeler Partner, Colorado